Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 83422E105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
BCLS SB Investco, LP
13D/A
Amendment 11
|
8.8% |
3/10/2026
Event 3/6/2026
|
|
| BCLS SB Investco, LP | 0% | ||
| Bain Capital Life Sciences Fund II, L.P. | 0.3% | ||
| BCLS II Investco, LP | 8.8% | ||
| BCIP Life Sciences Associates, LP | 0.1% | ||
| BCLS II Equity Opportunities, LP | 1.0% | ||
| Bain Capital Life Sciences Opportunities IV, L.P. | 5.4% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 9
|
9.9% |
2/21/2025
Event 2/19/2025
|
|
| RA Capital Management, L.P. | 9.9% | ||
| Peter Kolchinsky | 9.9% | ||
| Rajeev Shah | 9.9% | ||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||
|
BCLS SB Investco, LP
13D/A
Amendment 10
|
7.8% |
2/21/2025
Event 2/19/2025
|
|
| BCLS SB Investco, LP | 0.7% | ||
| Bain Capital Life Sciences Fund II, L.P. | 0.3% | ||
| BCLS II Investco, LP | 7.8% | ||
| BCIP Life Sciences Associates, LP | <0.1% | ||
| BCLS II Equity Opportunities, LP | 1.1% | ||
|
Camber Capital Management LP
13G/A
Amendment 1
|
0% |
2/14/2025
Event 12/31/2024
|
|
| Camber Capital Management LP | 0% | ||
| Stephen DuBois | 0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q1 | 7 | 5.93 k | $43.1 k |
| 2025 Q4 | 5 | 1.37 k | $7.73 k |
| 2025 Q3 | 5 | 12.5 k | $77.1 k |
| 2025 Q2 | 4 | 996 | $4.85 k |
| 2025 Q1 | 3 | 478 | $1.77 k |
| 2024 Q4 | 1 | 7.00 | $28.00 |
| 2024 Q3 | 1 | 7.00 | $49.00 |
| 2024 Q2 | 1 | 7.00 | $40.00 |
| 2024 Q1 | 1 | 6.00 | $80.00 |
| 2023 Q4 | 1 | 6.00 | $37.00 |
| 2023 Q3 | 1 | 6.00 | $15.00 |
| 2023 Q2 | 2 | 72.0 | $377.00 |
| 2023 Q1 | 2 | 72.0 | $341.00 |
| 2022 Q4 | 2 | 10.8 k | $58.1 k |
| 2022 Q3 | 62 | 63.5 M | $33.4 M |
| 2022 Q2 | 71 | 64.2 M | $39.5 M |
| 2022 Q1 | 81 | 69.3 M | $83.2 M |
| 2021 Q4 | 89 | 89.2 M | $156 M |
| 2021 Q3 | 100 | 77.0 M | $184 M |
| 2021 Q2 | 102 | 93.6 M | $342 M |
| 2021 Q1 | 124 | 92.6 M | $512 M |
| 2020 Q4 | 94 | 54.7 M | $415 M |
| 2020 Q3 | 62 | 25.5 M | $52.5 M |
| 2020 Q2 | 71 | 26.8 M | $79.1 M |
| 2020 Q1 | 79 | 19.6 M | $46.9 M |
| 2019 Q4 | 82 | 20.2 M | $89.7 M |
| 2019 Q3 | 79 | 32.1 M | $332 M |
| 2019 Q2 | 88 | 21.5 M | $129 M |
| 2019 Q1 | 84 | 17.2 M | $158 M |
| 2018 Q4 | 83 | 24.4 M | $653 M |
| 2018 Q3 | 80 | 18.7 M | $881 M |
| 2018 Q2 | 65 | 17.3 M | $617 M |
| 2018 Q1 | 59 | 15.9 M | $119 M |